Acer Therapeutics announces initiation of two trials of ACER-801

Acer Therapeutics announced the initiation of two Phase 2, single-arm investigator-sponsored trials evaluating ACER-801 in men with adenocarcinoma of the prostate. The POSH-MAP and PORT-MAP trials are being sponsored and conducted by The University of Kansas Cancer Center in partnership with Acer. POSH-MAP Trial: The POSH-MAP trial will evaluate the ability of ACER-801 to reduce hot flash frequency and severity and improve quality of life measures in men with prostate cancer following 28 days of therapy. Approximately 10 participants will receive 200mg of osanetant twice daily. Following the completion of treatment on day 28 participants will re-test hormone levels and report final patient outcome measures. More information on this trial can be found here. PORT-MAP Trial: The second trial, PORT-MAP, will evaluate the ability of ACER-801 to suppress testosterone production in men with prostate cancer within 28 days prior to a planned prostatectomy. Approximately 10 participants will receive 200mg of osanetant twice daily for 28 days, followed by a one week wash out period. Following the one week wash out period, patients will undergo a prostatectomy between days 35-39. The overall effect of osanetant on testosterone levels and the proportion of men achieving castrate levels of testosterone will be assessed, with hormone level assessment occurring on days 2, 3, 14, 28 and day 77. More information on this trial can be found here.